Tissue-Agnostic Cancer Therapy Approvals
Copyright © 2023 Elsevier Inc. All rights reserved..
Tumor-agnostic, or histology-agnostic, cancer therapy marks a groundbreaking evolution in the realm of precision oncology. In stark contrast to conventional cancer treatments that categorize malignancies based on their tissue of origin (eg, breast, lung, renal cell, etc), tumor-agnostic therapies transcend histologic boundaries, honing in on the genetic and molecular attributes of tumors, regardless of their location. This article offers a comprehensive review of the current landscape of tissue-agnostic cancer therapies and provides clinical insights to empower surgical oncologists with a deeper understanding of these innovative therapeutic approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Surgical oncology clinics of North America - 33(2024), 2 vom: 24. Feb., Seite 243-264 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gouda, Mohamed A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dabrafenib |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.soc.2023.12.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368918815 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368918815 | ||
| 003 | DE-627 | ||
| 005 | 20240229155902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.soc.2023.12.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM368918815 | ||
| 035 | |a (NLM)38401908 | ||
| 035 | |a (PII)S1055-3207(23)00092-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gouda, Mohamed A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tissue-Agnostic Cancer Therapy Approvals |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Tumor-agnostic, or histology-agnostic, cancer therapy marks a groundbreaking evolution in the realm of precision oncology. In stark contrast to conventional cancer treatments that categorize malignancies based on their tissue of origin (eg, breast, lung, renal cell, etc), tumor-agnostic therapies transcend histologic boundaries, honing in on the genetic and molecular attributes of tumors, regardless of their location. This article offers a comprehensive review of the current landscape of tissue-agnostic cancer therapies and provides clinical insights to empower surgical oncologists with a deeper understanding of these innovative therapeutic approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Dabrafenib | |
| 650 | 4 | |a Dostarlimab | |
| 650 | 4 | |a Entrectinib | |
| 650 | 4 | |a Larotrectinib | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Selpercatinib | |
| 650 | 4 | |a Tissue-agnostic | |
| 650 | 4 | |a Trametinib | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgical oncology clinics of North America |d 1997 |g 33(2024), 2 vom: 24. Feb., Seite 243-264 |w (DE-627)NLM075171023 |x 1558-5042 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2024 |g number:2 |g day:24 |g month:02 |g pages:243-264 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.soc.2023.12.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2024 |e 2 |b 24 |c 02 |h 243-264 | ||